Q2 2026 Payer Policy Updates: Medical Necessity Denial Changes for Hospital RCM Teams

The insights and clinical expertise shared in this post and included in the Q2 2026 Payer Policy Playbook draw on the expertise of Autumn Resch, Supervisor, Denials, and Melony Malone Norwood, Senior Clinical Review Analyst. We are grateful for their dedication to advancing clinical knowledge and their ongoing commitment to supporting our hospital and health system partners.

If Q1 2026 was about payers getting faster, Q2 is about them getting stricter—and more selective about what counts. The denials your team resolved at the front end are increasingly being reopened after discharge. The criteria set you relied on is changing mid-year, as payers like Medical Mutual swap MCG for InterQual. At the same time, a growing number of payers are making it clear that meeting InterQual or MCG is no longer the finish line; it’s the starting point. The revenue at stake hasn’t shrunk. The window to protect it has. These changes are already in effect. Here’s what your hospital revenue cycle management team needs to know:

The Shift You Can’t Front-Load Your Way Out Of

Post-service inpatient validation is quietly becoming one of the most consequential drivers of denials in the hospital revenue cycle—and one of the hardest to recover. Even when an admission was authorized up front, payers are reviewing the completed hospitalization and deciding after the fact whether inpatient level of care was medically necessary. The care has already been delivered, documentation opportunities are limited, and the denial often arrives at a stage where recovery is far more challenging. Several forces are converging to push this trend:

• stricter application of InterQual and MCG criteria,
• expanding payer audit programs,
• AI-driven review, and
• relentless enforcement of the observation-versus-inpatient line.

The result is that even medically appropriate admissions get challenged when documentation doesn’t unambiguously support inpatient-level care. Front-end and mid-cycle rigor are no longer sufficient on their own. Retrospective validation has become a deliberate payer strategy, shifting medical necessity reviews to a point where provider leverage is significantly reduced.

The most effective response is to leverage appeal outcomes as a source of organizational intelligence. Appeals teams have direct visibility into payer rationale, recurring documentation vulnerabilities, and emerging medical necessity trends. By systematically analyzing and sharing those insights, organizations can identify denial risk earlier, strengthen clinical documentation practices, and focus resources on admissions most likely to face retrospective review. In an environment where authorization is no longer synonymous with payment, appeal intelligence must evolve from a recovery tool into a denial prevention strategy.

To view the Q2 Payer Policy Playbook, click below:

Payer Policy Changes at a Glance

1. BCBS Michigan: A Modifier 25 Reprieve That Isn’t

Blue Cross Blue Shield of Michigan (BCBS) paused its planned Modifier 25 reimbursement cuts, but the delay shouldn’t be mistaken for a reversal.

• What changed: The proposed policy would cut reimbursement by 50% for non-preventive Evaluation and Management (E/M) services billed with Modifier 25 when reported the same day as a procedure by the same provider for the same patient. It applies to minor procedures with 0- or 10-day global periods (90-day global modifiers were an error and should be reported with Modifier 57), and targets office/outpatient codes 99202–99205 and 99212–99215. Several categories are excluded: preventive and administrative E/M, emergency department E/M services (99281–99285), office visits within one calendar day of an ED visit when the ED claim processes first, and procedures with no global period (“global XXX”). The minor procedure itself still pays at the full contracted rate. The change is expected to reach BCBSM commercial plans, Blue Care Network, Medicare Plus Blue, BCN Advantage, and the Federal Employee Program.
• Why it matters: The delay buys time, not stability. Enforcement behaviors often begin before a policy formally rolls out, and many BCBS plans have already stepped up review activity. Expect more determinations that the E/M service wasn’t separately identifiable, and heavier reliance on documentation specificity to defend it. Model your financial exposure now. This is a margin-compression risk, not a coding problem. Some payers are reducing or denying Modifier 25 E/M even when the billing is appropriate.

2. Medical Mutual: A Criteria Switch That Rewrites the Playbook

Effective April 13, 2026, Medical Mutual moved its medical necessity review criteria from MCG to InterQual. On paper, a vendor swap. In practice, a change in how medical necessity gets evaluated.

• What changed: MCG’s symptom-severity and response-to-treatment logic doesn’t map cleanly onto InterQual’s more prescriptive structure—objective clinical thresholds, episode-specific criteria, and defined progression pathways. Cases that comfortably met under MCG won’t automatically meet under InterQual without stronger documentation of clinical intensity and failed outpatient or lower-level care. Expect a bump in medical necessity denials early on, especially in borderline and short-stay cases, as everyone recalibrates.
• Why it matters: RCM teams must realign UR and case management narratives to InterQual’s expectations—clinical indicators, timing of interventions, and physician intent. Organizations that invest early in education, auditing, and provider communication will see more consistent determinations and stronger defensibility on appeal. Treat this as a shift in the standard, not a formatting change.

3. BCBS Massachusetts: Sepsis Must Be Shown, Not Stated

Blue Cross Blue Shield Massachusetts (BCBS) tightened its sepsis criteria for Q2 2026, raising the documentation bar for how a sepsis diagnosis must be clinically supported.

• What changed: BCBS MA updated its Sepsis-3 clinical criteria, tightening the definition around objective, organ dysfunction–driven evidence and closer alignment with national Sepsis-3 standards. The practical effect is more scrutiny on any sepsis case that leans on SIRS criteria or non-specific indicators without clear organ dysfunction. The high-risk profiles: early sepsis diagnoses without sustained abnormalities, cases that improved rapidly without inpatient-level intervention, and documentation still speaking in legacy SIRS terms with no clear tie to Sepsis-3.
• Why it matters: A sepsis diagnosis alone won’t carry an appeal. Documented acute organ dysfunction, and a clear clinical link to infection are what establish clinical validity and support medical necessity. Clinical severity must be demonstrated through objective findings and documented consistently throughout the record, not simply asserted.

4. UnitedHealthcare: More Denials Start with “Why Not Outpatient?”

UnitedHealthcare’s 2026 updates keep pressing on site-of-service management and medical necessity, and the expected result is more inpatient downgrades and a higher bar for admission-level justification.

• What changed: Two patterns are driving change. First, site-of-service denials are climbing as UHC scrutinizes whether care could have been delivered safely in a lower-acuity setting. Second, “why not outpatient” scrutiny is intensifying—denials increasingly cite the absence of documentation explaining why the service couldn’t be performed safely in observation or outpatient.
• Why it matters: Documentation must establish why inpatient care was necessary at the time of admission—the contraindications, the risk, the reason a lower level of care was genuinely unsafe. Meeting criteria isn’t enough when the denial is built on a site-of-service assumption.

5. Aetna: When Meeting Criteria Still Isn’t Enough

Aetna is increasingly denying claims based on internal medical necessity interpretations, not just standard criteria.

• What changed: Aetna’s 2026 posture reflects a move toward internal clinical policy enforcement that reaches beyond standard criteria—creating barriers even when InterQual or MCG benchmarks are clearly met. Appeals teams keep encountering denials rooted in Aetna’s own medical necessity interpretations, especially in respiratory, sepsis, and cardiac cases. A criteria-met case can still be denied on a proprietary policy overlay.
• Why it matters: A guideline-only appeal is easy for Aetna to dismiss, since its proprietary definitions can override “criteria were met” even when InterQual or MCG standards are satisfied. What holds up is a clinical narrative that spells out the patient’s specific severity, risk, and the reasons inpatient-level care was necessary—without it, the appeal has nothing left to stand on once the guideline argument is challenged.

6. Humana: The Denial Moved Upstream

Humana is intensifying prepayment scrutiny, delaying reimbursement, and increasing denials before claims even finalize.

• What changed: Humana’s 2026 updates expand prepayment review and clinical validation audits—pulling denial risk before the claim is even finalized. Prepayment clinical review is concentrating on high-cost, high-variance DRGs—sepsis, respiratory failure, malnutrition—which delays reimbursement and lifts initial denial rates. Alongside it, clinical validation denials are rising, with more cases challenged for insufficient clinical support behind the billed diagnosis.
• Why it matters:  Documentation must demonstrate diagnostic credibility with objective clinical evidence aligned to the record—not provider labeling alone. The question Humana is asking is whether the chart actually proves the diagnosis it’s billing.

7. Cigna: Observation-First, Short-Stay Under Fire

Cigna is pushing more cases toward observation status, increasing challenges to inpatient admissions.

• What changed: Cigna’s 2026 changes tighten utilization management and lean harder into observation-level pathways, producing more frequent challenges to inpatient admissions. The observation-first net is widening—conditions like chest pain, syncope, and mild CHF are increasingly expected to be managed in observation, driving inpatient-to-observation downgrades. At the same time, short-stay denials are rising: admissions under two midnights draw increased oversight, with denials citing thin documentation of expected length of stay or risk of deterioration.
• Why it matters: With observation-first as Cigna’s default assumption, an admission with no documented rationale is treated as a downgrade candidate from the start. Document the anticipated length of stay and the clinical risk supporting inpatient admission at the point of decision, not after the fact.

The Common Thread in Q2

Q1 was about payers moving faster. Q2 is about them moving the review—later in the process, deeper into proprietary policy, and further from the criteria language your appeals once leaned on.

Post-service validation shifts the battle to after discharge. Medical Mutual’s InterQual move changes what “meets criteria” even means. Aetna and UnitedHealthcare are denying past the guidelines. BCBS Massachusetts wants sepsis demonstrated, not declared. Humana wants the diagnosis proven before it pays. The common thread is the same one that closed out Q1: criteria citations are table stakes, and the recoverable revenue increasingly belongs to the teams that can tell the full clinical story—specific, documented, and defensible.

As retrospective and payer-specific review expands, that approach isn’t a differentiator anymore. It’s the baseline.

Aspirion’s denials management team combines clinical expertise, legal strategy, and AI-powered automation to help hospitals and health systems recover revenue from their most complex clinical denials. Ready to discuss what Q2 2026 means for your organization? Let’s talk.